Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 1, January-February, p. 63–67

Publication type: original article

Language: English

The Effects of Progesterone Selection on Psychological Symptoms in Hormone Replacement Therapy

Emel Kiyak Caglayan1,A,D, Mustafa Kara1,B, Sema Etiz2,B,F, Pinar Kumru3,C,D, Nurettin Aka2,F, Gultekin Kose2,

1 Department of Obstetrics and Gynecology, Bozok University Faculty of Medicine, Yozgat, Turkey

2 Department of Obstetrics and Gynecology, Haydarpasa Numune Research and Training Hospital, Istanbul, Turkey

3 Department of Obstetrics and Gynecology, Zeynep Kamil Research and Training Hospital, Istanbul, Turkey

Abstract

Objectives. The aim of this study is to evaluate the effects of hormone replacement therapy using dienogest and medroxyprogesterone acetate on psychological symptoms in perimenopausal and postmenopausal women.
Material and Methods. A total of 73 patients who sought treatment at the menopause units of the authors’ gynecology and obstetrics clinics between of November 2003 and October 2004 complaining of vasomotor symptoms were included in the study prospectively. The cases were divided into two groups: Group I (37 patients) was given 2 mg estradiol valerate and 2 mg dienogest, and Group II (36 patients) was given 2 mg estradiol valerate and 10 mg medroxyprogesterone acetate. The groups’ results in months 0 and 6 were compared through the evaluation of vasomotor and psychological symptom levels.
Results. No significant difference was found between the groups when the initial levels of vasomotor and psychological symptom subtypes were compared (p = 0.16). It was observed that all the psychological symptoms decreased in the 6th month in the group using dienogest in comparison with the initial situation, and that psychological symptoms increased in the group using medroxyprogesterone acetate in the evaluation performed in the 6th month compared with the initial levels. It was also found out that there was a statistically significant difference between the two groups when compared in terms of these symptoms (p < 0.0001).
Conclusion. While the use of dienogest normalizes the general psychological situation and sleep, it was observed that the use of medroxyprogesterone acetate (MPA) worsens the general psychological situation.

Key words

menopause, dienogest, medroxyprogesterone acetate, psychological symptoms.

References (18)

  1. Zeyneloglu HB: Ergeneli MTreatment of menopausal symptoms. J Drug Treat 1995, 8, 230–232.
  2. Haines JC, Xinq SM, Park KH, Holinka CF, Ausmanas KM: Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: The Pan-Asia menopause (PAM) study. Maturitas 2005, 52, 264–276.
  3. Nelson HD: Menopause. Lancet 2008, 371, 760–770.
  4. Limouzin-Lamonthe MA, Mairon N, Joyce CR, Le Gal M: Quality of life after the menapause: Influence of hormonal replacement therapy. Am J Obstet Gynecol 1994, 170, 618–624.
  5. Cohen LS, Soares CN, Poitras JR, Prouty J, Alexander AB, and Shifren JL: Short-term use of estradiol for depression in perimenopausal and postmenoupausal women: A preliminary report. Am J Psyhiatry 2003, 160, 1519–1522.
  6. Dag I: Validity and reliability of symptom checklist for university students (SCL-90-R). Turk Psikiyatri Derg 1991, 2, 5–12.
  7. Aydemir O, Koroglu E: Symptom checklist (SCL–90-R), clinical scales used in psychiatry. Eds.: Aydemir O, Koroglu E, Istanbul 2000, 33–41.
  8. Schneider HP, Rosemeier HP, Schnitker J, Gerbsch S, Turck R: Application and factor analysis of the menopause rating scale (MRS) in a postmarketing surveillance study of Climen. Maturitas 2000, 37, 113–124.
  9. Schneider HP: The role of antiandrogens in hormone replacement therapy. Climacteric 2000, 3, 21–27.
  10. Graser TA, Müler A, Mellinger U, Mück AO, Lippert TH, Oettel M: Continuous-combined treatment of the menopause with combinations of estradiol valerate and diogenest – a dose ranging study. Maturitas 2000, 35, 253–261.
  11. Qettel M, Graser T, Hoffmann H: The preclinical and clinical profile of diogenest A short overview. Drugs of Today 1999, 35, 3–12.
  12. Saletu B, Anderer P, Gruber D, Metka M, Huber J: Hormone replacement therapy and vigilance: double-blind, placebo-controlled EEG-mapping studies with an estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone in menopausal syndrome patients. Maturitas 2002, 43,165–181.
  13. Saletu B: Insomnia related to postmenopausal syndrome: Sleep laboratory studies on differences between patients and normal controls, and influence of an estrogen-progestogen combination with dienogest versus estrogen alone and placebo. Drugs of Today 2001, 37, 39–62.
  14. Von Schoultz B: Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment. Climacteric 2003, 6, 24–32.
  15. Graser TA, Hoffmann H, Zimmermann, Oettel M: New Oral Preparation for continuous combined hormone replacement therapy in postmenopausal women. Drugs of Today 2001, 37, 17–27.
  16. Wellington K, Perry CM: Estradiol valerate/dienogest. Drugs 2002, 62, 491–504.
  17. Kirkham C, Hahn PM, Van Vugt DA, Carmichael JA, Reid RL: A randomized, double-blind, placebo-controlled, cross-over trial to assess the side effects of medroxyprogesterone acetate in hormone replacement therapy. Obstet Gynecol 1991, 78, 93–97.
  18. Braden BB, Talboom JS, Crain ID, Simard AR, Lukas RJ, Prokai L: Medroxyprogesterone acetate impairs memory and alters the GABA’ergic system in aged surgically menopausal rats. Neurobiol Learn Mem 2010, 93, 444–453.
© Wroclaw Medical University